share_log

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $8

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $8

HC Wainwright & Co.维持对Karyopharm Therapeutics的买入,将目标股价下调至8美元
Moomoo 24/7 ·  03/01 07:10

HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price target from $10 to $8.

HC Wainwright & Co. 分析师爱德华·怀特维持Karyopharm Therapeutics(纳斯达克股票代码:KPTI)的买入并将目标股价从10美元下调至8美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发